Advancing Education on Biosimilars Act of 2021 became law 80 days after introduction, with one cosponsor, a Republican
Written by the Congressional Research Service [2]. 89 words.
Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.
- Committees
- Senate Health, Education, Labor, and Pensions Committee
- Policy area
- Health: 122 of 9,357 bills became law, 113th–118th (1.3%)
- Sponsor
- 3 of 248 bills enacted since 2013
- Text versions
- 4, from enrolled bill to public law · 684 words
- Subjects
- Drug safety, medical device, and laboratory regulationGovernment information and archivesHealth personnelLicensing and registrationsMedical educationPrescription drugs
- Latest action
- Apr 23, 2021: Became Public Law No: 117-8.
- Records
- Congress.gov · Bill text
Each bill appears once, under its strongest link. 2 in all.
Identical or companion · 1
- 117th H.R. 1873 Advancing Education on Biosimilars Act of 2021 R · Introduced
Related, per CRS or House · 1
- 117th H.R. 19 Lower Costs, More Cures Act of 2021 R · Introduced